Innovations in Oncology Learning Center From Guidelines to P

Overview
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity is 1.0
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Matthew Gubens, MD, MS
Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, CA
Dr. Gubens has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: Amgen, Johnson & Johnson, Merck, Trizell
Consulting fees: AnHeart, AstraZeneca, Atreca, BMS, Cardinal Health, Genentech, Gilead, Invitae, Johnson & Johnson, Merus, OncoHost
Other: DSMC for Samsung Bioepis
Luis Paz-Ares, MD, PhD
Head, Medical Oncology Department
Hospital Universitario 12 de Octubre
Madrid, Spain
Dr. Paz-Ares has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: AbbVie, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Gilead, GSK, Janssen, Lilly, Merck KGaA (Darmstadt, Germany), Mirati, MSD, Novartis, Pfizer, PharmaMar, Regeneron, Roche, Sanofi, Takeda
Other: Grants – AstraZeneca, BMS, MSD, Pfizer
Helena Yu, MD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, NY
Dr. Yu has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: AstraZeneca, Cullinan, Daiichi Sankyo, Erasca, Janssen, Novartis, Pfizer, SystImmune, Taiho
Consulting fees: AbbVie, Amgen, AstraZeneca, Daiichi Sankyo, Janssen, Taiho
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Lisa Hang, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Integrate clinical trial data into guideline-concordant testing and treatment planning for patients with non-small cell lung cancer (NSCLC)
- Develop clinical strategies informed by evidence and guidelines for the treatment of resectable NSCLC in the perioperative setting as well as the treatment of metastatic NSCLC with targeted therapies
- Evaluate emerging data with the potential to impact practice guidelines for patients diagnosed with NSCLC
- Implement therapeutic strategies tailored to specific regions, in accordance with NCCN Guidelines, for patients with NSCLC
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and pathologists, as well as all other physicians, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with lung cancer.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-133-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until 11/27/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AbbVie Inc., AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Lilly USA, LLC, and Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education, and the educational collaborators. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 11/27/2024
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.